ARTICLE | Clinical News
Avid Therapeutics regulatory update
March 21, 1994 8:00 AM UTC
Avid received notice of allowance for a U.S. patent covering hepadnavirus polymerases with DNA priming and reverse transcriptase activities. Avid holds an exclusive license under these claims from the Fox Chase Cancer Center. ...